Abstract
Ž
. hypoxic pulmonary hypertension in pigs. Methods: Pigs were subjected to acute, intermittent 15-min periods of hypoxia FiO 0.1 . . combination with BMS-182874 10 mg during repeated hypoxia were investigated. The ET-1-blocking properties of BMS-182874 were studied in vivo by infusion of ET-1 during normoxia and in vitro using isolated porcine pulmonary arteries. Results: The hypoxia-evoked Ž increase in mean pulmonary artery pressure was reduced by administration of BMS-182874 10 mgrkg i.v.; from 42 " 8 to 34" 4 . mmHg, P -0.05 and 30 mgrkg i.v.; from 38 " 4 to 30" 5 mmHg, P -0.05 . In addition, BMS-182874 at 30 mgrkg reduced the Ž y1 . pulmonary vascular resistance during hypoxia from 7.4 " 1.5 to 5.3 " 1.1 mmHgP min P l P -0.05 . The hemodynamic response to Ž . repeated hypoxia was reproducible in control animals and unaffected by the cyclo-oxygenase inhibitor diclophenac 3 mgrkg . Infusion of L-NNA alone resulted in an augmented pulmonary vasoconstriction during hypoxia; pulmonary arterial pressure from 35 " 6 to 43" 9 mmHg; P -0.05 and vascular resistance from 7.2 " 1.1 to 9.9 " 1.8 mmHgP min P l y1 ; P -0.05. L-NNA in combination with Ž . BMS-182874 10 mgrkg resulted in a hypoxic pulmonary vasoconstriction of similar magnitude as hypoxic baseline. In addition, BMS-182874 reduced the hemodynamic response to ET-1 in normoxic pigs and competitively antagonized the vasoconstrictor effect of ET-1 in isolated porcine pulmonary arteries. Conclusions: The non-peptide, selective ET receptor antagonist, BMS-182874, reduces
Introduction
The circulating levels of the potent vasoactive peptide Ž . w x endothelin ET 1 , have been found to be elevated in pathophysiological conditions associated with pulmonary w x hypertension 2 . The vascular effects of the isopeptide ET-1 are mediated by at least two classes of endothelin w x receptors 3,4 ; ET receptors, selective for ET- ET isopeptides and proposed to mediate either endothelium-dependent vasodilatation or when located on vascular w x smooth muscle cells vasoconstriction 5,6 . The most conspicuous effect of ET is sustained vasoconstriction that is slow in onset, in concordance with a regulation of ET release at the level of transcription. Indeed, several studies have indicated that ET-1 may act as a mediator of pulw x monary hypertension during chronic hypoxia 7,8 , whereas the time course for the contractile effects of ET has been Time for primary review 35 days.
0008-6363r98r$19.00 q 1998 Elsevier Science B.V. All rights reserved. ) considered to speak against a role for ET in acute hypoxia. However, physiological stimulation has been reported to produce rapid increases in the levels of circulating ET-1, indicating that endothelial cells may contain mature ET-1 w x 9 . In addition, immunoreactive ET-1 has been found within the cytoplasm of endothelial cells, indicating that preformed ET-1 may be present and available for rapid w x release in acute conditions 10 .
We have, in a large animal in vivo model, evaluated the effects of ET receptor antagonism using the selective, A w x non-peptide ET receptor antagonist, BMS-182874 11 , A during normoxia and acute hypoxic pulmonary hypertension in pigs. The possible involvement of cyclo-Ž . oxygenase products and nitric oxide NO in the response to hypoxia was evaluated using diclophenac and
To verify its ET-1-blocking properties, BMS-182874 was studied in vivo by infusion of ET-1 during normoxia and in vitro using isolated porcine pulmonary arteries. . Peninsula Labs., UK , dissolved in 0.9% NaCl, were administered through the Swan-Ganz catheter into the right ventricle or tested on isolated pulmonary arteries. L-NNA Ž . Sigma Medical, USA dissolved in 5% NaHCO solution 3 was infused i.v. via the left femoral vein. Substance P Ž . Peninsula Labs., UK in 0.9% NaCl was injected as bolus dose i.v. Pigs were left to rest for 30 min after surgery.
Methods

This
BMS-182874 and controls during normoxia and hypoxia
Following a baseline measurement, the animals were subjected to hypoxia during a 15-min period and the hemodynamic parameters were recorded at the end of this period. Ventilation with room air was thereafter reinstituted. After 1 h rest, the animals were randomized to either Ž . i.v. bolus injection of vehicle 35 ml 5% NaHCO only 3 Ž . Ž . n s 5 or BMS-182874, 10 mgrkg n s 7 or 30 mgrkg Ž . n s 7 . Thirty min after the injections, the protocol was repeated; hemodynamic parameters were obtained during normoxia and at the end of a 15-min period of hypoxia.
L-NNA during normoxia and hypoxia
Ž
. In another group of animals n s 6 , hemodynamic recordings were made during basal normoxia and 15 min of hypoxia. After a 75-min resting period, an i.v. infusion Ž y1 y1 . of L-NNA 40 mg P kg P h was started. After 15 min of L-NNA infusion, hemodynamic recordings were made first during normoxia, followed by measurements at the end of a 15-min hypoxic period. Substance P, known to induce vasodilatation mainly through endothelial-derived Ž . NO production, was given as bolus dose 5 mg before and during normoxic L-NNA infusion in order to verify the NO-blocking properties of the dose of L-NNA. The rate of the L-NNA infusion was based on preliminary experiments investigating the dose-response curve for L-NNA and Ž substance P in the present animal model n s 2, data not . shown .
L-NNA and BMS-182874 during normoxia and hypoxia
Ž
. In a separate group of animals n s 4 , the above Ž y1 y1 . protocol using L-NNA 40 mg P kg P h was repeated Ž . with the addition of BMS-182874 10 mgrkg , given i.v. 15 min before L-NNA infusion was started. The hemodynamic recordings were then repeated during normoxia and hypoxia. 
Diclophenac during normoxia and hypoxia
In another group consisting of 6 animals, hemodynamic parameters at the end of 15-min periods of hypoxia were Ž recorded before and after administration of diclophenac 3 . mgrkg , injected as an i.v. bolus dose 10 min before the second hypoxic period.
ET-1 infusion after BMS-182874 during normoxia
The dose-response relationship of cumulative infusion Ž y1 y1
of ET-1 10, 25, 50 and 100 ng P kg P min , 10 min . each dose into the right ventricle was established, during Ž . normoxia in controls n s 8 and after an i.v. bolus injec-Ž . tion of BMS-182874 10 mgrkg n s 4 .
AII after BMS-182874 during normoxia
To further confirm the selectivity of BMS-182874, the vascular effect of AII was also studied in separate groups Ž . of animals. AII was given either as a rapid injection 5 mg Ž into the right ventricle before and after BMS-182874 30
. Ž y1 mgrkg; n s 8 or as continuous infusion 150 ng P kg P y1 . Ž min for 30 min; n s 4 during which BMS-182874 30 . mgrkg was given after 10 min.
In Õitro experiments
Porcine pulmonary arteries with an inner diameter of 0.8-1.2 mm were obtained immediately postmortem from Ž . 6 pigs. The vessels 1-2 mm in length, n s 25 were mounted in 2 ml organ baths using two L-shaped holders w x 12 . Circular contractions were induced by Tyrode's solution in which NaCl had been replaced with KCl to give a final concentration of 127 mmolrl K q . Only vessels responding with two reproducible contractions were used
. n s 25 . ET-1 10 to 10 molrl was added to the organ baths in a cumulative fashion in controls as well as vessels incubated for 20 min with BMS-182874 10 y6 or 10 y5 molrl.
Statistics
Results are presented as means " standard deviation. Ž . Ordinary or repeated analysis of variance ANOVA followed by a Bonferroni multiple comparison test or the Student's t-test for unpaired samples were used for statisti-Ž . cal evaluation, GraphPad Software, Instat 2.01 . P -0.05 was considered significant. Table 1c resulted in a decrease of both the MPAP and PVR during the second hypoxic period compared to hypoxic baseline. In the systemic circulation, hypoxia resulted in a reduction in SVR, which was not significantly altered after administration of BMS-182874, while the MAP during hypoxia was reduced after BMS-182874 at 30 mgrkg. BMS-182874 Ž . 10 or 30 mgrkg did not induce any significant hemodynamic alterations during normoxia, although a tendency to lower PVR was noted. BMS-182874 administration did not Ž change arterial or venous blood gases pH, pO , pCO , 2 2 . not shown during normoxia or hypoxia. Vehicle was found to have no effects on hemodynamic parameters or blood gases.
Results
BMS-182874 and controls during normoxia and hypoxia
Ž . Ž In control animals
L-NNA during normoxia and hypoxia
. mg P kg P h did not evoke any significant hemody-Ž . namic changes during normoxia Table 2a . However, L-NNA infusion during the second hypoxia resulted in an increase in MPAP and PVR compared to first hypoxic period. In the systemic circulation, L-NNA infusion elevated MAP during hypoxia. Substance P at a dose of 5 mg evoked a prompt reduction of the MAP and SVR by 30 " 8 and 36 " 9%, respectively. After administration of L-NNA the effect of substance P was highly reduced Ž4 " 4% reduction of MAP P -0.001 and 3 " 6% in-. crease in SVR; P -0.01 compared to control .
L-NNA and BMS-182874 during normoxia and hypoxia
Ž Infusion of L-NNA in the presence of BMS-182874 10 . mgrkg did not evoke any hemodynamic changes during Ž . normoxia Table 2b . However, during the second hypoxia L-NNA infusion alone Table 2a , was  Ž  .  reduced Table 2b ; hypoxia 2 .
Diclophenac during normoxia and hypoxia
Ž
. Intravenous administration of diclophenac 3 mgrkg did not affect the hemodynamic parameters during normoxia or hypoxia. The pulmonary hypertensive effect of Ž hypoxia remained unchanged MPAP 37 " 6 mmHg; PVR 6.9 " 1.2 mmHgP min P l y1 before and MPAP 38 " 6 y1 . mmHg; PVR 7.4 " 2 mmHgP min P l after diclophenac .
ET-1 infusion after BMS-182874 during normoxia
Cumulative infusion of ET-1 resulted in a dose-dependent increase in PVR and SVR, while the CO decreased Ž . Ž y1 y1 . Fig. 1 . At the highest dose 100 ng P kg P min the ET-1 induced increase in PVR and SVR was attenuated in the animals receiving BMS-182874 compared to controls.
AII after BMS-182874 during normoxia
Ž . Bolus injection of AII 5 mg evoked an increase in Ž . MAP from 120 " 14 to 151 " 14 mmHg and MPAP Ž . from 19 " 4 to 26" 4 mmHg , which remained un-Ž changed after BMS-182874 administration MAP 147 " 11 . mmHg and MPAP 24 " 3 mmHg, respectively . Continu-Ž y1 y1
. ous infusion of AII 150 ng P kg P min for 30 min resulted in a stable, sustained increase in the pulmonary Ž vasotonus after 10 min of infusion; MPAP 169 " 11% . and PVR 153 " 23% of values before infusion , which was Ž not altered by BMS-182874 20 min after BMS-182874 at 30 mgrkg; MPAP 155 " 12% and PVR 148 " 19% of . control values before AII infusion . 
In Õitro experiments
Ž . Potassium 127 mmolrl evoked a strong contraction Ž . 5.8 " 1.6 mN of the isolated porcine pulmonary arteries which was unaffected by incubation with BMS-182874 Ž y6 y5
101 " 6 and 109 " 13%, at BMS 10 or 10 molrl q . compared to K -induced contractions, respectively . ET-1 caused a concentration-dependent contraction of the pulmonary arteries, which was dose-dependently attenuated Ž . by incubation with BMS-182874 Fig. 2 . The maximum response at the highest concentration of ET-1 was not altered by BMS-182874.
Discussion
Our present data show that ET receptor antagonism A with BMS-182874 can cause a dose-dependent, significant reduction of MPAP and PVR during hypoxia. The ET receptor blocking properties of BMS-182874 was apparent both in vivo and in vitro, while no effect was observed on the response to AII or K q . The in vitro experiments showing unaffected maximum response of ET-1 after BMS-182874 suggests competitive binding to the ET A w x receptor 11 . Although BMS-182874 has previously been w x shown to influence thromboxane A binding 11 , the use 2 of diclophenac in a concentration known to block cyclow x oxygenase activity 13 suggests that an involvement of cyclo-oxygenase products formed during hypoxia in the presently used experimental model is unlikely.
Our findings support earlier studies showing that the selective ET receptor antagonist, BQ-123, reduces the A pulmonary vasoconstriction during acute hypoxia in maw x w x ture fetal lambs 14 and in the rat 15 , which has also been shown for pulmonary hypertension evoked by chronic w x hypoxia 16 . Other studies have shown no effect of BQ-123 on hypoxia-induced vasoconstriction in isolated rat lung w x w x 17 or in the intact newborn lamb 18 . These contradictory findings could be explained by differences between the species studied, age of the animals and experimental model employed.
It can be argued that although BMS-182874 evoked no clear-cut changes in vascular tonus during normoxia, there was a tendency to pulmonary vasodilatation and these changes in baseline tonus would alter the vascular response to hypoxia. The experimental protocol was designed to exclude variations in baseline values and responses to hypoxia between different groups of animals. Consequently, all conclusions were made from changes within each group of animals. The hypoxic measurements were made at the end of each hypoxic period and are not likely to be explained by values during the normoxia preceding 15 min of hypoxia. However, a limited influence of the lower normoxic baseline on the magnitude of hypoxic response cannot be excluded. Although hypoxia has been shown to reduce endotheliumw x derived NO activity in the rat 20 , our data demonstrating an increase in hypoxic pulmonary vasoconstriction after inhibition of NO support that endogenous NO acts as a w x pulmonary vasodilator during acute hypoxia 19 .
Earlier studies have shown that ET, by activation of ET receptors, can induce vasodilation through the release B w x of NO and prostacyclin 21,22 . Our data using diclophenac indicate that vasodilatation, through the release of prostacyclin during hypoxia, is of less importance in the model studied. Furthermore, BMS-182874 in combination with L-NNA resulted in a hypoxic pulmonary vasoconstriction of similar magnitude as hypoxic baseline, whereas the group of animals receiving L-NNA alone demonstrated an augmented hypoxic response during the second hypoxic period. These data indicate that the effects of BMS-182874 are at least partly independent of NO production. However, the complex interactions between ET and NO pathways may also contribute to these results. Endothelial-derived NO has been described to reduce ET-1 production in w x the porcine aorta in vitro 23 . NO inhibition could thereby result in an up-regulation of the ET pathway during hypoxia. In addition, it is possible that ET antagonism could not abolish the vasodilator effect of BMS-182874 and diclophenac was found to have no effect during hypoxia. Moreover, we have, in a previous study, found that the non-selective ET receptor antagonist, bosentan, also reduces the hypoxic pulmonary vasoconstriction in the pig w x 25 .
In humans, the circulating plasma levels of ET-1 are low during normal conditions, but elevated in a variety of pathological conditions including pulmonary hypertension Ž w x. see 26 . Interestingly, mountaineers exposed to hypoxia at high altitude developed, within 22 h, elevated plasma ET-1 levels that correlated with estimated MPAP, indicating that ET may play a role in acute hypoxia in humans w x 27 .
In conclusion, the present study shows that the nonpeptidergic ET antagonist, BMS-182874, can reduce the A pulmonary hypertension in a large animal in vivo model of acute hypoxia, supporting the idea that ET may participate in pathological conditions associated with elevated PVR due to hypoxia.
